Press release
7th December 2022

SpectraCures signs Letter of Intent with Cheplapharm

SpectraCure aims at becoming the Market Authorization Holder of the photosensitizing drug used together with the Q-PRO system. SpectraCure has now signed a Letter of Intent with German pharma company Cheplapharm to secure global supply of the required active product ingredient (API).

SpectraCure has taken the strategic decision to become the Market Authorization Holder of the photosensitizing drug used as a part of the photodynamic therapy (PDT). This means that SpectraCure not only will sell the treatment platform Q-PRO, but also will, under its own trademark, market and sell the drug required to carry out the treatment.

SpectraCure aims to register and thereby legally own the new drug which gives full control over the commercialization and pricing.

The Letter of Intent signed between SpectraCure AB and Cheplapharm Arzneimittel GmbH is the basis of a strategic alliance for the global exclusive product supply from Cheplapharm to SpectraCure AB for the use in PDT treatment of prostate cancer. This cooperation is scheduled to be rolled out in the coming years.

> *"This is very important for SpectraCure, both strategically and commercially. We see interesting opportunities to bundle the delivery of the drug and the consumables required for our treatment and thereby, in addition to revenues from the Q-PRO platform itself, also build revenue streams from the drug",* comments Johan Folkunger, CEO SpectraCure.

This information is information that SpectraCure is obliged to make public according to the EU Market Abuse Regulation (EU No. 596/2014). The information was submitted, through the provision of the specified contact person, for publication on December 7, 2022, at 11:00 a.m.

For further information:
SpectraCure AB (publ) Johan Folkunger, CEO
E-Mail: jf@spectracure.com
Website: www.spectracure.com

SpectraCure is developing a treatment system for the elimination of internal solid cancer tumours. We focus initially on recurrent prostate cancer treatment, with an aim for the future to also be able to treat other forms of cancer, such as primary prostate cancer, breast and pancreatic cancer, as well as tumours in the head and neck region. The method is based on the Company's proprietary and patented treatment system consisting of hardware, a laser unit which carries out PDT treatment and treats the prostate itself in combination with the software, the patented software dose planning platform IDOSE®. The method makes it possible to focus the laser to expose the tumour for the optimal dose to achieve sufficient effect of the treatment. The treatment method has the potential to make interstitial PDT treatment accurate, precise and safe for each patient. The objective is that the patient besides having the tumour removed shall be able to

retain the quality of life, with limited side effects. We are conducting clinical trials as an important step in the continued development of the Company's treatment system.

The share is traded on Nasdaq First North Premier Growth Market under the ticker SPEC. G&W Fondkommission is the Certified Adviser of the company, e-mail: ca@gwkapital.se, telephone: +46(0) 8-503 000 50.